What is VIR?
Vir Biotechnology is a biotechnology company dedicated to creating novel therapies that leverage the immune system for the treatment and prevention of serious diseases. The company's core research focuses on antibody-based medicines and advanced immune technologies, targeting infectious diseases, cancer, and immunology. VIR's pipeline is strategically aimed at addressing high unmet medical needs, including conditions such as hepatitis delta, hepatitis B, and HIV.
How much funding has VIR raised?
VIR has raised a total of $260M across 2 funding rounds:
Unspecified
$250M
Grant
$10M
Unspecified (2020): $250M with participation from GlaxoSmithKline
Grant (2023): $10M led by Bill & Melinda Gates Foundation
Key Investors in VIR
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation is a prominent philanthropic organization focused on improving global health and reducing poverty. Its involvement suggests a commitment to VIR's mission of addressing critical health challenges.
GlaxoSmithKline
GSK plc is a global biopharmaceutical company with a strong focus on vaccines and specialty medicines. Its strategic investment in VIR highlights a shared interest in developing innovative treatments for infectious diseases and immunology.
What's next for VIR?
The substantial enterprise-level funding and recent strategic investment indicate VIR is poised for significant scaling and pipeline advancement. This capital infusion will likely accelerate the development and clinical trials of its promising therapeutic candidates. The company's focus on immune system modulation for critical diseases positions it as a key player in the evolving biotechnology landscape, with future growth expected to be driven by successful clinical outcomes and strategic partnerships.
See full VIR company page
